louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05334901: Performance of Curing Times and Intensitis
Official title: Effect of Different Curing Times and Intensities on The Performance of Compound Class II Bulk-Fill Resin Composite Restorations: (An In-Vivo and In-Vitro Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Clinical Performance
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2022-04-19
Enrollment: 28
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the study is to compare the effect of high intensity light cure (2200 mw/cm2) for 1 second with low intensity light cure (1200 mw/cm2) for 20 seconds on the clinical performance of bulk fill resin composite restorations in compound Class II cavities of posterior teeth

Detailed description: The prepared cavities will be conditioned with 35% phosphoric acid gel for15 seconds, then will be rinsed and dried with compressed air. Then application of universal adhesive system to all cavity with bond brush then light cured for 10 seconds using LED light curing unit (1200 mw/cm2). Extra-Fill bulk fill resin composite will be applied in onebulk increment and will be light polymerized for 1 second using (LED) light curing unit (2200 mw/cm2).for intervention group Extra-Fill bulk fill resin composite will be applied in one bulk increment and will be light polymerized for 20 seconds using (LED) light curing unit (1200 mw/cm2) fot control group

Eligibility criteria: Inclusion Criteria:

* Permanent premolars or molars.
* Moderate to deep compound class II cavities.
* Vital with the positive reaction to a cold thermal stimulus.
* Absence of parafunctional habits

Exclusion Criteria:

* Teeth with clinical symptoms of pulpitis such as spontaneous pain or sensitivity to pressure.
* Non-vital teeth.
* Secondary carious lesions.
* Advanced periodontal disease

Primary outcomes:
measure: Clinical performance
timeFrame: Change from the baseline at 6 months and12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Faculty of Dentistry
state: Cairo
city: Cairo
country: Egypt
facility: Faculty of Dentistry
Study officials:
affiliation: Cairo University
name: Roaa Azazy, Master
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02264301: Qingkailing Injection Versus Puerarin Injection on Withdrawal Rate of Corticosteroids in Patients With Active Rheumatoid Arthritis
Official title: The Effect of Qingkailing Injection on Corticosteroids Withdrawal Rate in Patients With Active Rheumatoid Arthritis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Rheumatoid Arthritis
Lead sponsor: Chengdu PLA General Hospital
Sponsor class: OTHER
First posted: 2014-10-15
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effect of Qingkailing injection versus Puerarin injection on withdrawal rate of corticosteroids in patients with active rheumatoid arthritis.


Eligibility criteria: Inclusion Criteria:

* with active RA
* without taking any other medication for the treatment of active RA in at least 4 last weeks
* aged from 18 to 75 years
* without conflict to the written, informed consent signed prior to the enrollment.

Exclusion Criteria:

* being included in other clinical trial within the last 4 weeks
* with abnormal liver or kidney function (more than 1 time above the high normal)
* with serious cardiovascular disease
* with hematologic disease
* being in pregnancy, lactation period or under a pregnancy plan
* with severe gastrointestinal disease
* with contraindication or being allergic to the test drugs
* being under the treatment of drugs within 1 previous week, that might affect the results of the trial, such as non-steroidal anti-inflammatory drugs, steroidal anti-inflammatory drugs, immunosuppressants, anti-ulcer drugs
* being not compatible for the trial medication, or other circumstances at the discretion of investigators
* without legal capacity or only with limited legal capacity.

Primary outcomes:
measure: Change from baseline in corticosteroids withdrawal rate at 24 weeks
timeFrame: At 0 week, 12 weeks, 24 weeks
Secondary outcomes:
measure: Change from baseline in Disease activity score in 28 joints(DAS28)
timeFrame: At 0 week, 12 weeks, 24 weeks
Other outcomes:
Locations:
city: Chengdu
country: China
facility: General Hospital of Chengdu Military Area Command PLA
Study officials:
References:
Clinical trial NCT02101801: Urine Drug Levels Related to Source of Water for Irrigation for Vegetable Crops Among Healthy Israeli Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Individuals
Keywords: environment, recycled wastewater, carbamazepine
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2014-04-02
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 68
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: Over 60% of crops in Israel are grown in recycled treated waste water. This study aims to determine whether minute quantities of drugs such as Carbamazepine can be found in individuals who ingest vegetables grown in waste water.

Detailed description: 40 healthy volunteers will undergo a food frequency questionnaire and ask to undergo a daily food diary.They will also be asked about drug exposure.

At baseline they will provide a urine and hair sample to determine presence of pharmaceuticals.

They will then undergo a crossover trial wih one week exposure to vegetables grown in recycled waste water or fresh water, with a three day wash out period. Participants will be asked to ingest a minimal amount of lettuce, carrots, peppers, tomatoes and lettuce during the study period.

During this period questionnaires will continue and urine samples will be collected every three days. The first compound to be tested will be carbamazepine, as it is stable in water.

It is important to note that vegetables provided to the participants are available in regular grocery stores.

Participants will be asked to drink bottled water throughout the study period . A sample of their home drinking water will also be tested for Carbamazepine as will a sample of the vegetables they consume.

Eligibility criteria: Inclusion Criteria:

* men and women
* age 18-68

Exclusion Criteria:

* ingestion of carbamazepine,
* pregnancy
* vegetarian
* pure organic diet

Primary outcomes:
measure: mean urine carbamazepine level in parts per billion
timeFrame: two weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization
Study officials:
affiliation: Hadassah Medical Organization
name: Ora Paltiel, MDCM
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01608204: Busulfan Pharmacokinetic Analysis and GST Pharmacogenetic Profile in Adults Undergoing Hematological Stem Cell Transplantation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Myeloid Leukemia
Keywords: Pharmacokinetics
Busulfan
Polymorphism
GST
MDR-1(p-Glycoprotein)
Acute Myeloid Leukemia adult patients
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2012-05-30
Enrollment: 63
Sex: ALL
Minimum age (years): 18
Maximum age (years): 67
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults suffering from AML who were selected to be treated by Hematological Stem Cell Transplantation

Brief summary: The correlation between Busulfan Pharmacokinetics in AML transplanted patients and their GST (A1,T1,M1 and P1), MDR-1 genetic profile. If a pre-genetic testing of those genes can be utilized as biomarkers of SOS and/or HGVHD. This study is not an interventional study it is only checking the GST gene and MDR-1 gene

Detailed description: BU levels are largely unpredictable, patients are often exposed to the toxic effects of inappropriate drug regimens before dose modifications can be made. Although the importance of TDM cannot be over emphasized, it entails trial and error and does not allow for pre- treatment dose optimization. This study, which provides an integration of genetic and pharmacokinetic data analysis of patients preconditioned for HSCT with high dose oral BU, aims to define biomarkers predictive of poor BU metabolism and clearance to prevent potential drug toxicity.This study is not an interventional study, only investigates the GST and MDR-1 genes in correlation with the "routine" Busulfan AUC done during the preparative regimen in HSCT for AML patients.

Eligibility criteria: Inclusion Criteria:

* Acute Myeloid Leukemia who are clinically selected for HSCT according to known protocols.

Exclusion Criteria:

* Unable to give informed consent

Primary outcomes:
measure: If GST and ABCB1 genes modify busulfan pharmacokinetics in AML patients who will be transplanted
timeFrame: end of BMT transplantation
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04940104: Change in Biting Force After Botox Injection
Official title: Change in Biting Force After Botilinium Toxin Injection and Its Effect on Peri Implant Bone Changes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bruxism
Lead sponsor: British University In Egypt
Sponsor class: OTHER
First posted: 2021-06-25
Enrollment: 20
Sex: FEMALE
Minimum age (years): 45
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Implant rehabilitation is a successful treatment option for edentulous patients. Decreasing bone loss around implants is an important target for all implantologists. It has been shown that pathological forces, such as bruxism, may in fact result in bone loss and eventual implant failure.

Botilinium Toxin is a material of many clinical uses. Beside its cosmetic applications, it has been used in the treatment of masseter muscle hypertrophy.

Purpose: To investigate the effect of botilinium toxin injection on biting forces, and its ultimate effect on peri-implant bone changes.


Eligibility criteria: Inclusion Criteria:

* Patients with a partially edentulous mandible, Kennedy Class I configuration, who are indicated for rehabilitation with partial implant overdenture prostheses, and who complained of Bruxism.

Exclusion Criteria:

* The presence of notable facial asymmetry.
* Severe malocclusion
* Pregnancy
* A history of any serious medical illness
* Drug allergy.

Primary outcomes:
measure: Change in biting force
timeFrame: 12 months
Secondary outcomes:
measure: Bone changes around implant
timeFrame: 12 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: The British University in EGYPT
Study officials:
References:
Clinical trial NCT01189604: Dose Rate Range Finding Study of Propofol for minimal-to Moderate Sedation on Upper & Lower Endoscopic Tests
Official title: A Multi-centre, Single-blind, Randomised, Parallel Group, Phase IIb Dose Rate Range Finding Study to Find Maintenance Dose Rate Range of ICI35,868 for the Minimal-to-moderate Sedation on Gastrointestinal Endoscopic Tests (Including Endoscopic Polypectomy)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Gastrointestinal Endoscopy
Gastrointestinal Polypectomy
Keywords: propofol endoscopy sedation
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
Collaborators: name: Johnson & Johnson K.K. Medical Company
First posted: 2010-08-26
Enrollment: 123
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Phase IIB study to find the optimal dose rate range of propofol to maintain minimal-to-moderate sedation for diagnostic gastrointestinal endoscopy and gastrointestinal polypectomy.


Eligibility criteria: Inclusion Criteria:

* Male or female (females of child bearing potential to confirm not pregnant via test or contraception)
* Be undergoing a non-emergent esophagogastroduodenoscopy (EGD) or colonoscopy, including polypectomy that shall be completed within 1 hour

Exclusion Criteria:

* American Society of Anesthesiologists (ASA) grade III, IV V and VI
* Baseline oxygen saturation\<90% (room air)
* Body Mass Index (BMI) \>=35

Primary outcomes:
measure: Modified Observers Assessment of Alertness/Sedation (MOAA/S) Score 2 Minutes From Beginning of Maintenance Period
timeFrame: 2 minutes from the beginning of the maintenance period
measure: Modified Observers Assessment of Alertness/Sedation (MOAA/S) Score 4 Minutes From Beginning of Maintenance Period
timeFrame: 4 minutes from the beginning of the maintenance period
Secondary outcomes:
measure: Patient Satisfaction With Sedation Instrument (PSSI) Questionnaire
timeFrame: 24 - 48 hours after completion of the procedure
measure: Blood Concentrations of Propofol
timeFrame: At the end of the initiation period and every 2 minutes during the maintenance period
measure: Modified Observers Assessment of Alertness/Sedation (MOAA/S) at End of Initiation Period
timeFrame: Last measurement in maintenance period (3 minutes for arms 1-5; 1 minute for arm 6, 5 minute for arm 7)
Other outcomes:
Locations:
city: Isesaki
country: Japan
facility: Research Site
state: Gunma
city: Moriya
country: Japan
facility: Research Site
state: Ibaragi
Study officials:
affiliation: Physician Group, Clinical Division, R&D, Astrazeneca K.K.
name: Masataka Date, M.D., Ph.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT03562104: Swallowing Disorders in Minimally Consciousness Patients (MCS)
Official title: Swallowing Disorders and Consciousness Alteration in Severe Traumatic Brain Injury Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Swallowing Disorder
Traumatic Brain Injury
Lead sponsor: University Hospital, Rouen
Sponsor class: OTHER
First posted: 2018-06-19
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Description of swallowing
Primary purpose: DIAGNOSTIC

Brief summary: This study aimed to characterize swallowing disorders in minimally consciousness patients after brain traumatic injury.

Detailed description: After inclusion, the patients will underwent a videofluoroscopy and the Wessex Head Injury Matrix.

Eligibility criteria: Inclusion Criteria:

* Legal representant signed
* Aged between 18 and 70 years
* Having a severe TBI (Glasgow \< 8)
* Without counterindication to underwent a VideoFluoroScopy
* Could hold a setting position

Exclusion Criteria:

* Pregnancy ongoing
* Having a pathologic al examination of IX, X, XII cranial nerve examination
* Massif faciale fracture
* Psychiatric illness
* Medical history of swallowing disorders

Primary outcomes:
measure: Stages of swallowing disorders
timeFrame: Day 1
Secondary outcomes:
measure: Correlation between Wessex Head Injury Matrix (WHIM) and stage of swallowing disorder
timeFrame: Day 1
Other outcomes:
Locations:
city: Bois-Guillaume
country: France
facility: Centre les Herbiers
city: Rouen
country: France
facility: UH Rouen
Study officials:
affiliation: University Hospital, Rouen
name: Eric VERIN, Pr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04560504: Effectiveness of Oculomotor Training in Parkinson's Disease
Official title: Oculomotor Deficits in Parkinson's Disease: Enhancing Eye Movement Performance and Dynamic Visual Acuity With Oculomotor Training Using a Pilot Randomized Clinical Trial Design
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Parkinson Disease
Oculomotor; Disorder
Keywords: Parkinson Disease
Oculomotor deficit
Oculomotor training
Dynamic vision
Lead sponsor: The Hong Kong Polytechnic University
Sponsor class: OTHER
Collaborators: name: University of California, Berkeley
name: Deakin University
name: Chinese University of Hong Kong
name: Hospital Authority, Hong Kong
First posted: 2020-09-23
Enrollment: 27
Sex: ALL
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Parkinson's disease (PD) is a common neurodegenerative disorder which is characterized by both motor and non-motor symptoms and usually affects people aged 50 years or above. Many studies showed eye movement deficits and visual changes in patients with PD.

Previous studies have also indicated that clinical eye movement training could enhance the functional performance of patients with various eye movement problems resulting from ocular and neurodegenerative diseases.

In this study, we will investigate the effectiveness of eye movement training on dynamic vision and functional performance in PD patients with oculomotor deficits.


Eligibility criteria: Inclusion Criteria:

* Parkinson's Disease diagnosed by a neurologist or geriatrician with the range of Stage

  1 to 4 (Hoehn and Yahr Classification)
* Able to speak and comprehend Cantonese dialect
* Able to travel independently

Exclusion Criteria:

* Any congenital eye problem (e.g. congenital strabismus or amblyopia in either eye) or any manifest eye diseases (e.g. macular degeneration, glaucoma, etc)
* Severe medical problems (e.g. stroke)
* Cognitive impairment (e.g. dementia)
* Presence of any psychiatric or neurological diseases (apart from Parkinson's disease) or receiving of any psychoactive pharmacological treatment
* Receiving any medication that is known to affect eye movement and cognitive function
* Previous formal vision rehabilitation or oculomotor intervention

Primary outcomes:
measure: Smooth Vergence eye movements
timeFrame: Change from baseline at week 4 and change from baseline at week 12
Secondary outcomes:
measure: Oculomotor characteristics
timeFrame: Change from baseline at week 4 and change from baseline at week 12
measure: Sentence reading performance
timeFrame: Change from baseline at week 4 and change from baseline at week 12
measure: Passage reading performance
timeFrame: Change from baseline at week 4 and change from baseline at week 12
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Allen MY Cheong
Study officials:
affiliation: The Hong Kong Polytechnic University
name: Allen Ming Yan Cheong, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02351804: Does Perineural Dexamethasone Prolong Duration of a Nerve Block?
Official title: Does Perineural Dexamethasone Prolong Duration of an Adductor Canal Block When Controlling for a Systemic Effect? A Paired, Randomized, Blinded, Study in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Healthy Volunteers
Keywords: US-guided peripheral nerve block
Anesthetics, Local
duration
Sensation
adductor canal block
lower limb
Adjuvants, Anesthesia
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2015-01-30
Enrollment: 20
Sex: MALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate whether dexamethasone as an adjuvant to ropivacaine for adductor canal block increases duration of the sensory block, when controlling for a systemic effect using a paired design and bilateral blocks.

The investigators hypothesize that adding dexamethasone to ropivacaine will prolong block duration compared with ropivacaine + placebo.


Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiologists class 1
* Body Mass Index 18-30

Exclusion Criteria:

* Allergy to study medication
* Earlier trauma or surgery to lower limb
* Diabetes Mellitus
* Alcohol or drug abuse
* Daily intake of opioids or steroids last 4 weeks
* Daily intake of any analgesics last 48 hours

Primary outcomes:
measure: Difference in duration of sensory block between dexamethasone and placebo assessed as cold sensation with an alcohol swab
timeFrame: 0-36 hours
Secondary outcomes:
measure: Difference between dexamethasone and placebo in the duration of a sensory block assessed by pin-prick
timeFrame: 0-36 hours
measure: Difference between dexamethasone and placebo in the duration of a sensory block assessed as maximum pain during a tonic heat stimulation test
timeFrame: 0-36 hours
measure: Difference between dexamethasone and placebo in the duration of a sensory block assessed as warmth detection threshold
timeFrame: 0-36 hours
measure: Difference between dexamethasone and placebo in the duration of a sensory block assessed as heat pain detection threshold
timeFrame: 0-36 hours
measure: Difference in maximum pain scores between dexamethasone and placebo during block and after recovery of normal sensation
timeFrame: 0-36 hours
Other outcomes:
Locations:
city: Gentofte
country: Denmark
facility: Department of Anaesthesia-Surgery-Intensive Care, Gentofte Hospital
state: Hellerup
Study officials:
affiliation: Rigshospitalet, Denmark
name: Pia Jæger, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: